NCT00639158
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
See it on ClinicalTrials.gov ↗542 people
55%
45%
298 womenmiddle line = equal numbers244 men
- Phase
- PHASE3
- Paid for by
- Abbott
- Finished
- —
- Health conditions
- Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 55.4 years
- Age 65+
- 20.1%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Women who are pregnant or plan on becoming pregnant, or women who are lactating.”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Women who are pregnant or plan on becoming pregnant, or women who are lactating.”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Subjects must agree to use adequate birth control methods and to adhere to the American Heart Association (AHA) Diet.”
Study titles and rules are shown in their original English.